Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: Modulation of inflammation and oxidative stress

Biologics: Targets and Therapy

Volumn 5, Issue , 2011, Pages 7-19

  Garcia Bailo, Bibiana ^a,b   El Sohemy, Ahmed ^b   Haddad, Pierre S ^c   Arora, Paul ^a,b   Benzaied, Firas ^d   Karmali, Mohamed ^a,b   Badawi, Alaa ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

Author keywords

Inflammation; Innate immunity; Micronutrients; Oxidative stress; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; C REACTIVE PROTEIN; CALCITRIOL; CATALASE; CITRATE CALCIUM; COLECALCIFEROL; GLITAZONE DERIVATIVE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; HYDROPEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; METFORMIN; NITRIC OXIDE; NITROGEN DIOXIDE; REACTIVE OXYGEN METABOLITE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL SURVIVAL; CYTOKINE PRODUCTION; DIABETES CONTROL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INHIBITION KINETICS; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; RABBIT; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; VITAMIN SUPPLEMENTATION;

EID: 79953183067     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S14417     Document Type: Review

References (169)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-787.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projection for 2030. Diabetes Care. 2004;27(5):1047-1053.
3. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan J P. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195-1200.
4. Venkataraman R, Nanda NC, Baweja G, Parikh N, Bhatia V. Prevalence of diabetes mellitus and related conditions in Asian Indians living in the United States. Am J Cardiol. 2004;94(7):977-980.
5. Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62(7):1087-1095.
6. Savage DB, Petersen K F, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension. 2005; 45(5):828-833.
7. Stumvoll M, Goldstein BJ, van Haeften T W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467): 1333-1346.
8. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes. 2010;3:173-186.
9. Pickup JC. Inflammation and activate innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3): 813-823.
10. Evans JL, Maddux BA, Goldfne ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005;7(7-8): 1040-1052.
11. Alberti KG. Treating type 2 diabetes-today's targets, tomorrow's goals. Diabetes Obes Metab. 2001;3 Suppl 1:S3-S10.
12. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4-7.
13. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, infammation, and atherosclerosis. Am J Cardiol. 2002;90(5A):27G-33G.
14. Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2422-2429.
15. Singh U, Jialal I. Anti-inflammatory effects of alpha-tocopherol. Ann N Y Acad Sci. 2004;1031:195-203.
16. Isharwal S, Misra A, Wasir JS, Nigam P. Diet and insulin resistance: a review and Asian Indian perspective. Indian J Med Res. 2009;129(5): 485-499.
17. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005;4(1):5.
18. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086): 944-948.
19. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11): 1286-1292.
20. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241-1248.
21. Cone JB. Infammation. Am J Surg. 2001;182(6):558-562.
22. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000; 343(5):338-344.
23. Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch Physiol Biochem. 2009;115(4): 176-190.
24. Hotamisligil GS. Infammation and metabolic disorders. Nature. 2006; 444(7121):860-867.
25. Hotamisligil GS, Arner P, Caro J F, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5): 2409-2415.
26. Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19(1): 10-16.
27. Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab. 2006; 8(2):136-145.
28. Rosen P, Nawroth P P, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001;17(3):189-212.
29. West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000; 17(3):171-180.
30. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80(1):123-127.
31. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab. 2003;88(10):4673-4676.
32. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625.
33. Evans JL, Goldfne ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52(1):1-8.
34. Facchini FS, Hua N W, Reaven GM, Stoohs RA. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Radic Biol Med. 2000;29(12):1302-1306.
35. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939-1945.
36. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces infammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52(12):2882-2887.
37. Calder PC, Albers R, Antoine JM, et al. Infammatory disease processes and interactions with nutrition. Br J Nutr. 2009;101 Suppl 1:S1-S45.
38. Evans JL, Goldfne ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599-622.
39. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067-2072.
40. Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: a systematic review. Ophthalmic Physiol Opt. 2008;28(6):503-523.
41. Harding AH, Wareham NJ, Bingham SA, et al. Plasma vitamin C level, fruit and vegetable consumption, and the risk of new-onset type 2 diabetes mellitus: the European prospective investigation of cancer-Norfolk prospective study. Arch Intern Med. 2008;168(14):1493-1499.
42. Wang H, Zhang ZB, Wen RR, Chen J W. Experimental and clinical studies on the reduction of erythrocyte sorbitol-glucose ratios by ascorbic acid in diabetes mellitus. Diabetes Res Clin Pract. 1995;28(1):1-8.
43. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr. 1995;14(4):387-392.
44. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr. 1993;57(5):650-656.
45. Rizzo MR, Abbatecola AM, Barbieri M, et al. Evidence for anti-inflammatory effects of combined administration of vitamin E and C in older persons with impaired fasting glucose: impact on insulin action. J Am Coll Nutr. 2008;27(4):505-511.
46. Carta S, Castellani P, Delfno L, Tassi S, Vene R, Rubartelli A. DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol. 2009;86(3):549-555.
47. Navab M, Gharavi N, Watson AD. Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care. 2008;11(4):459-464.
48. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115-134.
49. Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004; 16(1):3-9.
50. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15(2):74-80.
51. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994;15(2):81-88.
52. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.
53. Montecucco F, Steffens S, Mach F. Insulin resistance: a pro inflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Infamm. 2008;2008:767623.
54. Aguirre V, Uchida T, Yenush L, Davis R, White M F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275(12):9047-9054.
55. Guzik TJ, West NE, Black E, et al. Vascular super oxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86(9):E85-E90.
56. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular super oxide production in human diabetes mellitus: role of NAD(P) H oxidase and endothelial nitric oxide synthase. Circulation. 2002; 105(14):1656-1662.
57. Vega-Lopez S, Devaraj S, Jialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med. 2004;52(1):24-32.
58. Oberg B P, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and infammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65(3):1009-1016.
59. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001; 44(7):834-838.
60. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl. 2000;77:S3-S12.
61. Kashiwagi A, Asahina T, Ikebuchi M, et al. Abnormal glutathione metabolism and increased cytotoxicity caused by H2O2 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia. 1994;37(3):264-269.
62. Scott JA, King GL. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci. 2004;1031:204-213.
63. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S232-S236.
64. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25(3):487-496.
65. Turko I V, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol. 2001;281(6):H2289-H2294.
66. Browning LM, Jebb SA. Nutritional influences on inflammation and type 2 diabetes risk. Diabetes Technol Ther. 2006;8(1):45-54.
67. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001;108(4):635-636.
68. Douillet C, Bost M, Accominotti M, Borson-Chazot F, Ciavatti M. Effect of selenium and vitamin E supplementation on lipid abnormalities in plasma, aorta, and adipose tissue of Zucker rats. Biol Trace Elem Res. 1998;65(3):221-236.
69. Paolisso G, Gambardella A, Tagliamonte MR, et al. Does free fatty acid infusion impair insulin action also through an increase in oxidative stress? J Clin Endocrinol Metab. 1996;81(12):4244-4248.
70. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002; 51(7):2005-2011.
71. Rudich A, Tirosh A, Potashnik R, Khamaisi M, Bashan N. Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes. Diabetologia. 1999;42(8):949-957.
72. Rudich A, Kozlovsky N, Potashnik R, Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol. 1997; 272(5 Pt 1):E935-E940.
73. Tirosh A, Rudich A, Potashnik R, Bashan N. Oxidative stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes. Biochem J. 2001;355(Pt 3):757-763.
74. Haber CA, Lam TK, Yu Z, et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab. 2003; 285(4):E744-E753.
75. Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes. 2003;52(9): 2338-2345.
76. Paolisso G, D'Amore A, Volpe C, et al. Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients. Metabolism. 1994;43(11):1426-1429.
77. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: fndings from the Third National Health and Nutrition Examination Survey. Diabetes. 2003;52(9): 2346-2352.
78. Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 2001;54 Suppl 2:S29-S33.
79. Maritim AC, Sanders RA, Watkins J B III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1): 24-38.
80. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79(8 Suppl):1527-1534.
81. Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatory pathway. Curr Opin Investig Drugs. 2005;6(10):979-987.
82. Hundal RS, Petersen K F, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109(10):1321-1326.
83. Gumieniczek A, Krzywdzinska M, Nowak M. Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two ant diabetics, pioglitazone and repaglinide. Exp Lung Res. 2009;35(5): 371-379.
84. Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS. Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Curr Pharm Des. 2009;15(27):3094-3107.
85. Fukuzawa M, Satoh J, Qiang X, et al. Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Diabetes Res Clin Pract. 1999; 43(3):147-154.
86. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169(3): 453-459.
87. Brighenti F, Valtuena S, Pellegrini N, et al. Total antioxidant capacity of the diet is inversely and independently related to plasma concentration of high-sensitivity C-reactive protein in adult Italian subjects. Br J Nutr. 2005;93(5):619-625.
88. Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr. 2007; 98 Suppl 1:S29-S35.
89. Soory M. Relevance of nutritional antioxidants in metabolic syndrome, ageing and cancer: potential for therapeutic targeting. Infect Discord Drug Targets. 2009;9(4):400-414.
90. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30(4): 980-986.
91. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. Review: the role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocriol Metabol. 2007;92(6):2017-2029.
92. Haddad PS, Azar GA, Groom S, Boivin M. Natural health products, modulation of immune function and prevention of chronic diseases. Evid Based Complement Alternat Med. 2005;2(4):513-520.
93. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000; 71(1 Suppl):343S-348S.
94. Liu CT, Sheen LY, Lii CK. Does garlic have a role as an antidiabetic agent? Mol Nutr Food Res. 2007;51(11):1353-1364.
95. Weisberg S P, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated infammation and diabetes in mouse models of diabesity. Endocrinology. 2008;149(7):3549-3558.
96. Srinivas L, Shalini VK. DNA damage by smoke: protection by turmeric and other inhibitors of ROS. Free Radic Biol Med. 1991;11(3): 277-283.
97. Srivastava R, Srimal RC. Modification of certain inflammation-induced biochemical changes by curcumin. Indian J Med Res. 1985; 81:215-223.
98. Vuksan V, Stavro M P, Sievenpiper JL, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care. 2000; 23(9):1221-1226.
99. Sprietsma JE, Schuitemaker GE. Diabetes can be prevented by reducing insulin production. Med Hypotheses. 1994;42(1):15-23.
100. Hashemipour M, Kelishadi R, Shapouri J, et al. Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children. Hormones (Athens). 2009; 8(4):279-285.
101. Song Y, Wang J, Li XK, Cai L. Zinc and the diabetic heart. Biometals. 2005;18(4):325-332.
102. Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008;14(5-6):353-357.
103. Prasad AS, Bao B, Beck F W, Kucuk O, Sarkar FH. Antioxidant effect of zinc in humans. Free Radic Biol Med. 2004;37(8):1182-1190.
104. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vazquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr. 2007; 26(5):573-580.
105. Teegarden D, Donkin SS. Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev. 2009;22(1):82-92.
106. Holick M F. Diabetes and the vitamin d connection. Curr Diab Rep. 2008;8(5):393-398.
107. Anan F, Takahashi N, Nakagawa M, Ooie T, Saikawa T, Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism. 2005;54(4):552-558.
108. Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem. 2009;42(10-11):1174-1177.
109. Szathmary EJ. The effect of Gc genotype on fasting insulin level in Dog rib Indians. Hum Genet. 1987;75(4):368-372.
110. Hirai M, Suzuki S, Hinokio Y, et al. Variations in vitamin D-binding protein (group-specifc component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. J Clin Endocrinol Metab. 2000;85(5):1951-1953.
111. Baier LJ, Dobberfuhl AM, Pratley RE, Hanson RL, Bogardus C. Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab. 1998;83(8):2993-2996.
112. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006; 29(3):650-656.
113. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immuno-logical functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 2003;49(2):277-300.
114. Griffn MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr. 2003; 23:117-145.
115. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004; 80(6 Suppl):1717S-1720S.
116. DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 2001;15(14):2579-2585.
117. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334-338.
118. Riachy R, Vandewalle B, Kerr Conte J, et al. 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology. 2002;143(12):4809-4819.
119. Van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1-2): 93-101.
120. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5): 307-314.
121. Chiu KC, Chu A, Go VL, Saad M F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004; 79(5):820-825.
122. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care. 2005;28(5):1228-1230.
123. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care. 2006; 29(10):2244-2246.
124. Need AG, O'Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol (Oxf). 2005;62(6):738-741.
125. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2813-2818.
126. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care. 2005;28(12):2926-2932.
127. Fliser D, Stefanski A, Franek E, Fode P, Gudarzi A, Ritz E. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest. 1997;27(7):629-633.
128. Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner. 1986;1(3):187-192.
129. Ljunghall S, Lind L, Lithell H, et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance-a prospective randomized double-blind study. Acta Med Scand. 1987;222(4):361-367.
130. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1994;59(5):1083-1087.
131. Nilas L, Christiansen C. Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes. 1984;8(5):407-411.
132. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
133. Von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr. 2010;103(4): 549-555.
134. Wannamethee SG, Lowe GD, Rumley A, Bruckdorfer KR, Whincup PH. Associations of vitamin C status, fruit and vegetable intakes, and markers of infammation and hemostasis. Am J Clin Nutr. 2006; 83(3):567-574.
135. Aguirre R, May JM. Infammation in the vascular bed: importance of vitamin C. Pharmacol Ther. 2008;119(1):96-103.
136. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A. 2001;98(17):9842-9846.
137. Cahill L, Corey PN, El-Sohemy A. Vitamin C defciency in a population of young Canadian adults. Am J Epidemiol. 2009;170(4):464-471.
138. Young IS, Tate S, Lightbody JH, McMaster D, Trimble ER. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozo-tocin diabetic rat. Free Radic Biol Med. 1995;18(5):833-840.
139. Ford ES, Liu S, Mannino DM, Giles WH, Smith SJ. C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr. 2003;57(9): 1157-1163.
140. Hamer M, Chida Y. Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis. J Hypertens. 2007;25(12):2361-2369.
141. Woodward M, Lowe GD, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97(4): 785-797.
142. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GD. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1999; 104(2):246-257.
143. Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H. C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 2003; 122(1):135-141.
144. Gao X, Bermudez OI, Tucker KL. Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. J Nutr. 2004; 134(4):913-918.
145. Holt EM, Steffen LM, Moran A, et al. Fruit and vegetable consumption and its relation to markers of infammation and oxidative stress in adolescents. J Am Diet Assoc. 2009;109(3):414-421.
146. Lu Q, Bjorkhem I, Wretlind B, Diczfalusy U, Henriksson P, Freyschuss A. Effect of ascorbic acid on microcirculation in patients with type II diabetes: a randomized placebo-controlled cross-over study. Clin Sci (Lond). 2005;108(6):507-513.
147. Chen H, Karne RJ, Hall G, et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol. 2006; 290(1):H137-H145.
148. Tousoulis D, Antoniades C, Vasiliadou C, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood fow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart. 2007;93(2):244-246.
149. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutr Metab. 1995;39(4):217-223.
150. Adolfsson O, Huber BT, Meydani SN. Vitamin E-enhanced IL-2 production in old mice: naive but not memory T cells show increased cell division cycling and IL-2-producing capacity. J Immunol. 2001;167(7):3809-3817.
151. Han SN, Adolfsson O, Lee CK, Prolla TA, Ordovas J, Meydani SN. Vitamin E and gene expression in immune cells. Ann N Y Acad Sci. 2004;1031:96-101.
152. Devaraj S, Jialal I. α-Tocopherol decreases interleukin-1β release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol. 1999;19:1125-1133.
153. Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic Biol Med. 2000; 28(12):1795-1805.
154. Salonen JT, Nyyssonen K, Tuomainen T P, et al. Increased risk of non- insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ. 1995;311(7013): 1124-1127.
155. Reunanen A, Knekt P, Aaran RK, Aromaa A. Serum antioxidants and risk of non-insulin dependent diabetes mellitus. Eur J Clin Nutr. 1998;52(2):89-93.
156. Mayer-Davis EJ, Costacou T, King I, Zaccaro DJ, Bell RA. Plasma and dietary vitamin E in relation to incidence of type 2 diabetes: the Insulin Resistance and Atherosclerosis Study (IRAS). Diabetes Care. 2002;25(12):2172-2177.
157. Ward NC, Wu JH, Clarke M W, et al. The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Hypertens. 2007;25(1):227-234.
158. Wu JH, Ward NC, Indrawan A P, et al. Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem. 2007;53(3):511-519.
159. Liu S, Lee IM, Song Y, et al. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. Diabetes. 2006;55(10):2856-2862.
160. Ble-Castillo JL, Carmona-Diaz E, Mendez JD, et al. Effect of alpha-tocopherol on the metabolic control and oxidative stress in female type 2 diabetics. Biomed Pharmacother. 2005;59(6):290-295.
161. Reaven PD, Herold DA, Barnett J, Edelman S. Effects of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 1995;18(6):807-816.
162. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A. 2009;106(21):8665-8670.
163. Buijsse B, Feskens EJ, Kwape L, Kok FJ, Kromhout D. Both alpha-and beta-carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men. J Nutr. 2008;138(2):344-350.
164. Devaraj S, Leonard S, Traber MG, Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med. 2008;44(6):1203-1208.
165. Belisle SE, Leka LS, Delgado-Lista J, Jacques PF, Ordovas JM, Meydani SN. Polymorphisms at cytokine genes may determine the effect of vitamin E on cytokine production in the elderly. J Nutr. 2009; 139(10):1855-1860.
166. Barclay C, Procter KL, Glendenning R, Marsh P, Freeman J, Mathers N. Can type 2 diabetes be prevented in UK general practice? A lifestyle-change feasibility study (ISAIAH). Br J Gen Pract. 2008; 58(553):541-547.
167. Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review. Am J Prev Med. 2005;28(1):126-139.
168. Frost G, Leeds A, Trew G, Margara R, Dornhorst A. Insulin sensitivity in women at risk of coronary heart disease and the effect of a low glycemic diet. Metabolism. 1998;47(10):1245-1251.
169. Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol. 2008;101(10A):75D-86D.